MYGN Stock Recent News
MYGN LATEST HEADLINES
NEW YORK CITY, NY / ACCESS Newswire / May 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.
NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.
SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences: The BofA Securities 2025 Health Care Conference – fireside chat at 6:00 pm ET (updated) on Wednesday, May 14, 2025. Goldman Sachs 46 th Annual Global Healthcare Conference – fireside chat at 2:00 pm ET on Wednesday, June 11, 2025.
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.
NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.